Navigation Links
AMT: Glybera(R) Lowers Pancreatitis Incidence Significantly
Date:1/28/2009

AMSTERDAM, The Netherlands, January 28 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today during the Phacilitate Cell & Gene Therapy Forum new data showing that one treatment of its lead product Glybera(R) results in a long term significant and clinically important lowering of the incidence of acute pancreatitis in Lipoprotein Lipase Deficient patients. Recurrent acute pancreatitis is the most debilitating complication of Lipoprotein Lipase Deficiency (LPLD) and is associated with significant morbidity and mortality.

To date only one patient from the two clinical trials had an acute pancreatitis during the long-term follow-up, while seven episodes of pancreatitis would have been expected based on the observational studies in the same patients. This equals a lowering of the incidence of pancreatitis from 0.33 per patient per year to 0.05 for both trials. The data were obtained from two observational and two interventional clinical studies with 22 patients and follow up data from 1 to 3.5 years after the treatment. The studies result in a total of more than 38 patient years worth of data.

Other positive effects of Glybera are the disappearance or reduction of fat accumulations in the skin or retina. The data also confirm that the treatment is well-tolerated and safe.

AMT has developed Glybera as an effective treatment for patients with the rare genetic disorder LPLD. Because of a defective gene, LPLD patients do not produce an enzyme that normally breaks down a certain type of fat carrying particles in the blood. Glybera is a gene therapy, which restores the enzyme (lipoprotein lipase) activity required to process the fat carrying particles. LPLD patients have extremely high fat levels in their blood, resulting in recurrent and potentially lethal pancreatitis as well as an increased risk of cardiovascula
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AMT Prepares for Submission of Marketing Authorization Dossier for AMT-011 (Glybera(R))
2. AMT Intends to Incorporate Additional Data to its Marketing Authorization Dossier for Glybera(R)
3. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
4. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
5. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
6. Kmart Lowers Flu Shot Price to $10
7. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
8. BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients
9. New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients
10. Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation
11. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 P&S Market ... market overview, trends, DRO analysis, market segmentation, ... developments, competitive scenario and top competitor profiles ... Market Development and Demand Forecast to 2020  ... Explore more about global biosensors ...
(Date:7/30/2015)... , July 30, 2015   Gaumard® Scientific ... to UNI®, the world,s first operating system to ... now available exclusively to Gaumard users. UNI® version ... launched Newborn Tory™ S2200, as well as improvements ... of clinical measures such as EtCO 2 .  ...
(Date:7/30/2015)... VIEJO, Calif. , July 30, 2015 /PRNewswire/ ... aspiring to eliminate all preventable hospitalization, recently received ... that its Remote Patient Intelligence (RPI) solution meets ... the FDA intends to exercise "Enforcement Discretion." ... "are not subject to further FDA regulatory requirements ...
Breaking Medicine Technology:Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 2Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 3FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 2FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 3
(Date:7/31/2015)... ... July 31, 2015 , ... The Mount Sinai Health System will work with ... potential of related, experimental treatments. The collaboration moves into the next phase with the ... one of five state licenses to produce and dispense medical marijuana. , Mount ...
(Date:7/31/2015)... ... July 31, 2015 , ... Recently, ZKB ... of Ohio, Western Division (Case No. 3:15-cv-00397) involving the Implanon® contraceptive implant ... spontaneous migration of their Implanon® implants, inability to locate the implants, unsuccessful and ...
(Date:7/31/2015)... ... July 31, 2015 , ... Florida ... novel catheter that was developed for targeted delivery of fluids to selected sites ... treated at Florida Hospital Tampa with the device that provides direct, local delivery ...
(Date:7/31/2015)... ... July 31, 2015 , ... Awarded to only the Top 10 hair ... that they are the latest recipients of the Center of Clinical Excellence for ... the worldwide leaders in the science of hair transplant. , Parsa Mohebi Hair Restoration ...
(Date:7/31/2015)... ... July 31, 2015 , ... Healthpointe ... a newly redesigned website at Healthpointe.net. The new website will feature a sleek ... The redesign serves to provide smoother interactions between patients and the Healthpointe clinics ...
Breaking Medicine News(10 mins):Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:Healthpointe Announces Newly Redesigned Website 2
... ... been developed. Experienced weight loss physicians have raised the HCG diet caloric daily allowance from ... diet protocol written 50 years ago. The physician’s goal with this new HCG diet protocol ... patients. , ...
... ... place on May 6, 2010. Two years in the planning and development, the cutting-edge ... nonsurgical laser treatments for varicose veins and spider veins. , ... Prescott, AZ (PRWEB) April 27, 2010 -- Prescott Vein Specialties ...
... with chronic kidney disease have more severe anemia than white ... a multicenter study led by Johns Hopkins Children,s Center to ... Journal of Kidney Disease . The findings suggest that ... may be at play, raising the question whether current guidelines ...
... studies finds that patients, research participants and journal readers ... disclosed, in part because those financial ties may influence ... the April 26 issue of Archives of Internal ... ties to the pharmaceutical, biotechnology and medical device industries ...
... ─ Tiny, melanin-covered nanoparticles may protect bone marrow from ... at Albert Einstein College of Medicine of Yeshiva University ... these particles into human patients may hold promise in ... issue of the International Journal of Radiation Oncology, ...
... are most likely to be good candidates upon death, ... U.S. researchers have developed a new tool that may ... donors, a development that could potentially boost organ donation ... often good candidates for organ donation when they die ...
Cached Medicine News:Health News:Breakthrough in HCG Weight Loss Therapy 2Health News:Breakthrough in HCG Weight Loss Therapy 3Health News:New Varicose Vein Treatment Center Opens in Prescott, Arizona 2Health News:Anemia tougher to tackle in black children with kidney disease 2Health News:Patients, clinicians favor disclosure of financial ties to industry 2Health News:Patients, clinicians favor disclosure of financial ties to industry 3Health News:Novel nanoparticles prevent radiation damage 2Health News:Novel nanoparticles prevent radiation damage 3Health News:Novel nanoparticles prevent radiation damage 4Health News:Test Spots Potential Organ Donors Among Coma Patients 2
The RapidBARBITURATE test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of barbiturates and in human urine specimens above a cut-off level of 3...
... With membrane parasite ... and cytoplasm as antigen. ... different antigens than the ... possible to use two ...
Elisa test for qualitative detection of Total antibodies to Trypanosoma Cruzi in human serum or plasma....
Silicone ICD lead...
Medicine Products: